Investment Opportunity
Dermomat is building a platform of antibacterial, mechanotransductive biomaterials that don't just cover chronic wounds — they rebuild the biological environment needed to heal them.
One platform, two products, a multi-billion-dollar market, and a team with the science and clinical depth to translate it.
The Opportunity
Chronic wounds are one of the most expensive and least-solved problems in modern healthcare — and the market for advanced solutions is large and growing.
$12B
Global advanced wound care market in 2025, forecast to ~$18–23B by the mid-2030s
18.6M
People worldwide affected by diabetic foot ulcers alone
1 in 3
People with diabetes who develop a foot ulcer in their lifetime
The drivers are structural and accelerating: ageing populations, the global rise in diabetes and obesity, and more complex surgical caseloads. Advanced-stage ulcers can cost upwards of $50,000 per wound episode, and chronic wounds carry high rates of infection, recurrence and amputation. This is a market where better biology translates directly into lower system cost.
Most products manage the surface; the biology stays stuck. The majority of wound-care products are passive — barriers that protect and absorb while waiting for the body to heal itself. In a chronic wound, that biology is precisely what has stalled, driving a costly cycle of repeat dressings, prolonged care, infection and, too often, amputation.
The gap in the market: a product that actively restarts healing rather than simply covering it.
A core technology that expresses as two complementary products lets Dermomat address a far wider range of wounds from a single scientific foundation, while sharing development, IP and manufacturing know-how.
Antibacterial mechanotransductive dermal scaffold
A structured scaffold that supports the wound bed while actively guiding cell infiltration, vascularisation and remodelling. Targets diabetic foot ulcers, venous leg ulcers, pressure ulcers, burns and surgical reconstruction.
Injectable regenerative dermal matrix
A flowable matrix that conforms to deep cavities and irregular defects where fixed scaffolds can't reach, extending the platform into complex, hard-to-dress wounds.
Diabetes, obesity and ageing are expanding the at-risk pool faster than current solutions can serve it.
Mechanobiology, ECM engineering and tissue engineering have matured to the point of clinical translation.
Reimbursement is shifting toward products that demonstrably close wounds and reduce downstream cost.
Talk with us about our technology and invest in the future of wound healing. Contact our team to learn more about our innovation, and investment opportunities today.